- AGC will expand its Spanish facilities to increase production capacity by 1.3 times.
- A new R&D facility will start operations in March 2021.
- The expanded production facility is scheduled to begin in May 2022.
- AGC acquired the site from Boehringer Ingelheim in March 2019.
Expansion Plans
AGC Inc. is set to expand its pharmaceutical production facilities in Spain, increasing capacity by 1.3 times. This expansion includes the establishment of a new R&D facility, which will begin operations in March 2021, while the expanded production facility is scheduled to start in May 2022.
Acquisition Background
AGC Pharma Chemicals Europe, the subsidiary responsible for this expansion, was acquired from Boehringer Ingelheim in March 2019. The acquisition aimed to bolster AGC's synthetic pharmaceutical production capabilities in Europe, providing active pharmaceutical ingredients and intermediates.
Market Growth
The synthetic pharmaceutical CDMO market is experiencing over 7% annual growth, with AGC's contracts growing even faster. To meet this demand, AGC is upgrading existing facilities and introducing a new micronization facility to enhance production capabilities.
Strategic Initiatives
Under its AGC plus management policy, AGC is focusing on life-sciences, including the pharmaceutical CDMO business, targeting sales of 100 billion yen by 2025. The company is investing in facilities across Japan, the US, and Europe to provide consistent, high-quality services globally.
